PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
- Resource Type
- Review Article
- Source
- In
Critical Reviews in Oncology / Hematology April 2021 160 - Subject
- Language
- ISSN
- 1040-8428